NMRA Neumora Therapeutics, Inc.
Company Analysis
Latest News
🟢 Neumora Therapeutics is trading 6.34% up today after recent selloff
Neumora Therapeutics is trading 6.34% up at $0.88, with the rebound appearing to follow the recent selloff rather than a confirmed corporate catalyst. -...
🔴 Neumora Therapeutics is trading 10.35% down today amid biotech weakness after disappointing Ionis trial news
Neumora Therapeutics is trading 10.35% down at $0.90 after broader biotech weakness intensified following disappointing clinical-trial news from Ionis...
🔴 Neumora Therapeutics falls 5.7% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Neumora Therapeutics is trading 10.53% down today as coverage points to failed Phase 3 depression trials
Neumora Therapeutics is trading $1.02 (-10.53%) lower, with no new company-specific announcement, earnings release, or analyst action clearly explaining the...
🔴 Neumora Therapeutics is trading 7.01% down today with no clear company-specific catalyst identified
Neumora Therapeutics is trading 7.01% down at $1.06, continuing a multiday decline from $1.33 on September 1, 2026, with no clear company-specific catalyst...
🔴 Neumora Therapeutics is trading 5% down today as hotter-than-expected August producer inflation weighs on markets
Neumora Therapeutics is trading 5% down at $1.14 as broader markets weaken following hotter-than-expected August producer inflation. - The S&P 500, Nasdaq...
🟢 Neumora Therapeutics is trading 16.81% up in pre-market — No clear company-specific catalyst identified
Neumora Therapeutics is trading 16.81% up now at $1.40 in pre-market, with no clearly reported company-specific catalyst identified. - Searches found no...
🟢 Neumora Therapeutics is trading 7.2% up in after-hours trading with no clear catalyst
Neumora Therapeutics is trading 7.2% up in after-hours trading at $1.34, after closing at $1.25 on September 8, 2026, with no verified company-specific...
BlackRock Discloses New 4.21% Stake in Neumora Therapeutics
BlackRock Inc. has acquired a new position in Neumora Therapeutics, Inc., purchasing 7,791,869 shares, according to a recent Form 13F filing with the...
🟢 Neumora Therapeutics is trading 5.6% up today as broader biotech-sector gains
Neumora Therapeutics is trading 5.6% up at $1.41 after opening higher on September 2, 2026, amid broad biotechnology-sector gains. - The sector’s XBI ETF is...
🟢 Neumora Therapeutics is trading 6.77% up in pre-market with no clear company-specific catalyst identified
Neumora Therapeutics is trading at $1.42 (+6.77%) in pre-market on September 1, 2026, with no clear company-specific catalyst identified. - The latest...
🟢 Neumora Therapeutics is trading 10.07% up in pre-market; catalyst remains unclear
Neumora Therapeutics is trading 10.07% up at $1.53, with no clearly identified company-specific announcement on August 31, 2026. - The latest official release...
🔴 Neumora Therapeutics falls 5.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Neumora Therapeutics is trading 5.41% up in pre-market; no clear company-specific catalyst reported
Neumora Therapeutics is trading at $1.56 (+5.41%), with no clearly reported company-specific catalyst for August 28, 2026. - Recent coverage includes August...
🔴 Neumora Therapeutics is trading 5% down today with no clear catalyst identified
Neumora Therapeutics is trading at $1.54, down 5.21%, with no clear company-specific catalyst identified for August 24, 2026. - The latest company update...
🟢 Neumora Therapeutics rises 5.9% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Neumora Therapeutics falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Neumora Therapeutics is trading 5.59% up today without a confirmed catalyst
Neumora Therapeutics is trading 5.59% up at $1.60 despite broader market weakness on August 18, 2026, with no new company-specific announcement clearly...
Neumora Therapeutics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 19, 2026
Neumora Therapeutics is projected to report a Q2 2026 consensus revenue of $0.00 and an EPS loss of -$0.24, with its current price of $1.59 trading...
🔴 Neumora Therapeutics is trading 5.6% down today after August 14 earnings release and leadership transition
Neumora Therapeutics is trading at $1.51 (-5.59%) after investors absorbed its August 14, 2026 earnings release and leadership transition. - Although its...